In this episode of “Synaptic,” Kasari talks about the need for inclusion in educating autistic children, what drew her into the autism research field, and growing up on the family farm.

Changes to the DSM-5’s diagnostic criteria for autism were meant to add clarity, but they also generated new questions.

This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.

A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.

Autistic people tend to drop out of Medicaid once they reach adulthood in states that don’t waive the income restrictions on enrollment.

The drug clemastine and other compounds that fortify the protective sheath around neurons may prove therapeutic for some genetic neurodevelopmental conditions.

Experiments offer clues to why certain mutations are associated with autism in some people and not others.

New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.

Autistic toddlers who receive a personalized intervention at about 18 months of age gain more abilities than those who start the therapy nine months later.

A shift in astrocyte secretions may explain the atypical firing patterns of neurons derived from people with fragile X syndrome.